| Name | etravirine |
|---|---|
| Synonyms |
Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
etravirine 4-({6-Amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl}oxy)-3,5-dimethylbenzonitrile tmc 125 |
| Description | Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. |
|---|---|
| Related Catalog | |
| In Vitro | TMC125 is highly active against wild-type HIV-1 (50% effective concentration [EC50]=1.4 to 4.8 nM) and shows some activity against HIV-2 (EC50=3.5 μM). TMC125 also inhibits a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus. TMC125 has activity for 19 viruses with EC50 of < 5 nM[1]. |
| In Vivo | Etravirine has a high genetic barrier to the development of resistance. In phase IIb trials in treatment-experienced patients, including those infected with virus resistant to NNRTIs and protease inhibitors (PIs), TMC125 is active against HIV resistant to currently available NNRTIs, with a similar tolerability profile to that of the control group[2]. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 637.4±65.0 °C at 760 mmHg |
| Melting Point | 265ºC (dec.) |
| Molecular Formula | C20H15BrN6O |
| Molecular Weight | 435.277 |
| Flash Point | 339.3±34.3 °C |
| Exact Mass | 434.049072 |
| PSA | 120.64000 |
| LogP | 4.19 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.703 |
| Storage condition | -20°C Freezer |
| Hazard Codes | Xi |
|---|